The whole-body PBPK model for ritonavir, a potent time-dependent inhibitor of CYP3A4.
Within this repository, we distribute a whole-body PBPK model of ritonavir, encompassing competitive and time-dependent inhibition and induction effects of CYP3A4 by ritonavir. The model was assessed using observed data on ritonavir pharmacokinetics and its interactions with midazolam, triazolam, and oxycodone. The detailed information on model development and evaluation was described in [1].
Everyone interacting in the Open Systems Pharmacology community (codebases, issue trackers, chat rooms, mailing lists etc...) is expected to follow the Open Systems Pharmacology code of conduct.
We encourage contribution to the Open Systems Pharmacology community. Before getting started please read the contribution guidelines. If you are contributing code, please be familiar with the coding standard.
The model code is distributed under the GPLv2 License.
[1] Zheng L, Zhang W, Olkkola KT, Dallmann A, Ni L, Zhao Y, et al. Physiologically Based Pharmacokinetic Modeling of Ritonavir-Oxycodone Drug Interactions and Its Implication for Dosing Strategy. Eur J Pharm Sci. 2024:106697.